.jpg)
15 hours ago
3
Article content
WINNIPEG, Manitoba, March 17, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) announces that Frontiers in Antibiotics has published a peer-reviewed article authored by researchers from Kane Biotech and the University of Manitoba, detailing important scientific advancements in the fight against antibiotic-tolerant biofilms.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
Key messages of the article as it relates to Kane’s revyve wound gel include:
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
- revyve Antimicrobial Wound Gel demonstrated strong activity against antibiotic-tolerant biofilms, a major barrier in the treatment of chronic wounds.
- In both in vitro and ex vivo models, revyve eliminated mature Staphylococcus aureus and Pseudomonas aeruginosa biofilms, even after they had developed high levels of antibiotic tolerance.
- Following antibiotic pre-treatment, which generated highly antibiotic-tolerant cells, revyve achieved large log-scale reductions in surviving populations, often driving bacterial counts below detectable limits within 24–72 hours.
- In summary, these results show that revyve effectively inactivates stubborn biofilms, supporting its potential as a valuable advanced-wound-care tool for improving healing outcomes in chronic, biofilm-laden wounds.
Article content
Article content
US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel
Article content
The forthcoming publication, titled “Efficacy of a Novel Thermo-Reversible Wound Gel Against Antibiotic Tolerant Biofilm,” underscores Kane’s growing leadership in biofilm-targeted therapeutics and adds to the expanding body of evidence supporting innovative approaches to wound and burn management. First-authored by Dr. Jeyachchandran Visvalingam, Internal R&D Leader, and including contributions from Dr. Sarvesh Logsetty, renowned burn and trauma surgeon at the Max Rady College of Medicine, University of Manitoba, the study contributes meaningful insights into how thermo-reversible antibiofilm and antimicrobial technologies can address one of the most persistent challenges in modern wound care.
Article content
Article content
Frontiers in Antibiotics is a peer-reviewed, open-access journal that focuses on antibiotic development, resistance, and clinical applications.
Article content
The article can be viewed here.
Article content
“Having our research published in Frontiers in Antibiotics as an open-access article is an important milestone for Kane Biotech as we continue to commercialize revyve across wound and burn care markets,” said Dr. Robert Huizinga, Interim CEO of Kane Biotech. “This peer-reviewed journal is recognized for its rigorous scientific standards and transparent review process. This publication reinforces the strength of our technology and supports our mission to bring advanced, biofilm-targeted solutions to patients.”
Article content
About Kane Biotech Inc. (TSX-V:KNE)
Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.
English (US)